(S)-2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(((5-fluoro-2-((S)-pent-4-en-2-yloxy)benzyl)oxy)methyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetic acid → (2S)-2-(tert-butoxy)-2-[(20S,22Z)-15-fluoro-4,20,26-trimethyl-11,19,25-trioxa-1,5,7,8-tetraazapentacyclo[24.2.2.16,9.02,7.013,18]hentriaconta-2,4,6(31),8,13,15,17,22-octaen-3-yl]acetic acid

Participants

Reaction Conditions

Reaction Steps

To a solution of (S)-2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(((5-fluoro-2-((S)-pent-4-en-2-yloxy)benzyl)oxy)methyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetic acid (20 mg, 0.031 mmol) in DCE (75 mL) were added (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride/Hoveyda-Grubbs II (4.90 mg, 7.83 μmol) and copper(I) iodide (5.96 mg, 0.031 mmol) and the mixture was stirred at 90° C. After 3 h, the reaction was concentrated. The crude material was purified via preparative HPLC to afford (2S)-2-(tert-butoxy)-2-[(20S,22Z)-15-fluoro-4,20,26-trimethyl-11,19,25-trioxa-1,5,7,8-tetraazapentacyclo[24.2.2.16,9.02,7.013,18]hentriaconta-2,4,6(31),8,13,15,17,22-octaen-3-yl]acetic acid (9.8 mg, 0.016 mmol, 50.2% yield). 1H NMR (500 MHz, DMSO-d6) δ 7.19-6.92 (m, 3H), 6.57-6.38 (m, 1H), 6.11-5.87 (m, 1H), 5.81-5.64 (m, 1H), 5.59-5.46 (m, 1H), 4.94-4.47 (m, 4H), 4.45-4.31 (m, 1H), 4.01-3.78 (m, 1H), 3.74-3.47 (m, 1H), 2.51 (br. s., 13H), 1.71-1.49 (m, 1H), 1.33-1.06 (m, 14H). LCMS (M+H) calcd for C33H44FN4O6: 611.32. found: 611.5.

Provenance & Evidence